SCHEMBL19979716

SCHEMBL19979716

C=CCOC(=O)N1CCCC1c1nc(CNC(=O)OC(C)(C)C)no1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.39
TSHR P16473 5/20 0.39
EPHA2 P29317 1/20 0.38
KDR P35968 1/20 0.38
EPHB4 P54760 1/20 0.38
KMT2A Q03164 3/20 0.37
L3MBTL1 Q9Y468 3/20 0.37
MEN1 O00255 2/20 0.37
CYP1A2 P05177 2/20 0.37
LMNA P02545 4/20 0.35
GAA P10253 1/20 0.35
TP53 P04637 2/20 0.34
MAPT P10636 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
GLA P06280 1/20 0.34
DPP4 P27487 1/20 0.33
PREP P48147 1/20 0.33
DPP8 Q6V1X1 1/20 0.33
DPP9 Q86TI2 1/20 0.33
DPP7 Q9UHL4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19979715 1.00 ALDH1A1 (0.39) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL19979749 0.90 CYP3A4 (0.39) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL19979742 0.90 CYP3A4 (0.39) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL19979747 0.82 DPP4 (0.40) ALDH1A1TSHRDPP4PREPDPP8
SCHEMBL19979809 0.82 CYP1A2 (0.38) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL30147129 0.81 CYP1A2 (0.41) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL19979810 0.81 DPP4 (0.35) ALDH1A1GAADPP4PREPDPP8
SCHEMBL19975457 0.74 MAOA (0.39) ALDH1A1TSHREPHA2KDREPHB4
SCHEMBL29176525 0.73 CYP1A2 (0.38) EPHA2KDREPHB4L3MBTL1CYP1A2
SCHEMBL29176527 0.73 CYP1A2 (0.38) EPHA2KDREPHB4L3MBTL1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018053302-A1 MACROCYCLIC COMPOUNDS FOR THE INHIBITION OF INDOLEAMINE-2,3-DIOXYGENASE ACTIVITY AND USE THEREOF ENSEMBLE THERAPEUTICS CORPORATION (US) 2018-03-22 WO disclosed